IDH1 and myeloproliferative neoplasm: HMA-Ven is currently the standard induction therapy for patients with MPN-BP, most of whom would have been on JAK2 inhibitor therapy during disease progression [25]; we have no objections to the use of alternative induction regimens and, in the presence of IDH mutations, single-agent therapy with an IDH inhibitor might be less toxic than HMA-Ven and adequate enough as a bridge toward AHSCT [37].